Table 1.
Characteristics of patients included in the study, for which proteasome activity was assessed by activity-based probes profiling. MLL-AF4: chimeric protein of mixed-lineage leukemia (MLL)-AF4, TCF3-PBX1: fusion protein of transcription factor 3 and PBX homeobox 1, HHD: high hyperdiploidy, AML1: acute myeloid leukemia 1. * According to ALL-BFM 2000 risk stratification criteria.
| BCP-ALL | T-ALL | |
|---|---|---|
| No. of patients | 28 | 21 |
| Sex: male/female (%) | 9 (32%)–19 (68%) | 18 (86%)–3 (14%) |
| Age (median; min–max) | 9.7 (0.3–17.6) | 5 (2–18.8) |
| Sample characteristics | ||
| Diagnosis (%) | 22 (78.6%) | 17 (81%) |
| Relapse (%) | 6 (21.4%) | 4 (19%) |
| Risk at diagnosis (%) * | ||
| Standard risk | 9 (40.9%) | 1 (5.9%) |
| Medium risk | 0 | 7 (41.2%) |
| High risk | 5 (22.7%) | 6 (35.3%) |
| Very high risk | 8 (36.4%) | 3 (17.6%) |
| Cytogenetic aberrations in BCP-ALL | ||
| MLL-AF4_t (4;11) | 5 | |
| TCF3-PBX1_t (1;19) | 5 | |
| HHD | 3 | |
| AML1 amplification | 1 | |
| Immunophenotype in T-ALL (%) | ||
| Cortical | 10 (47.6%) | |
| Mature | 7 (33.3%) | |
| Pre | 4 (19.1%) |